Literature DB >> 24629207

Equol producers can have low leptin levels among prediabetic and diabetic females.

Naoki Sakane1, Kazuhiko Kotani2, Kokoro Tsuzaki3, Kaoru Takahashi4, Takeshi Usui5, Shigeto Uchiyama6, Shinji Fujiwara7.   

Abstract

OBJECTIVES: Soy isoflavones have received great attention for their beneficial effects on health and disease, i.e., in patients with diabetes. Equol is a biologically active isoflavone-related metabolite with interindividual differences in its production. The current study investigated the relationship between an equol-producing state and the levels of adipocytokine markers in a prediabetic and diabetic population. SUBJECTS AND METHODS: A total of 79 subjects (34 males/45 females) in a prediabetic or diabetic state recruited from the general population were examined regarding their ability to produce equol using urine samples. Clinical data, such as age, smoking as well as anthropometric and biochemical variables, including body mass index (BMI), lipids, insulin, glucose, hemoglobin A1c, leptin and adiponectin, were recorded.
RESULTS: Equol producers exhibited lower leptin and leptin/BMI than non-producers among females. Simple correlation tests and stepwise multiple regression analyses revealed a significant inverse correlation between the leptin/BMI and equol-production. This relationship was not found in males.
CONCLUSIONS: Female equol producers can have favorable metabolic traits in relation to leptin metabolism in this population. Further studies are needed to confirm these results.
Copyright © 2014. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24629207     DOI: 10.1016/j.ando.2014.01.003

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  5 in total

Review 1.  Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives.

Authors:  Carmela Santangelo; Alessandra Zicari; Elisabetta Mandosi; Beatrice Scazzocchio; Emanuela Mari; Susanna Morano; Roberta Masella
Journal:  Br J Nutr       Date:  2016-02-16       Impact factor: 3.718

2.  Research protocol: effect of natural S-equol on blood pressure and vascular function--a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension.

Authors:  Zhao-min Liu; Suzanne C Ho; Yu-ming Chen; Yao Jie Xie; Zhi-guan Huang; Wen-hua Ling
Journal:  BMC Complement Altern Med       Date:  2016-03-01       Impact factor: 3.659

3.  Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial.

Authors:  Sara Hazim; Peter J Curtis; Manuel Y Schär; Luisa M Ostertag; Colin D Kay; Anne-Marie Minihane; Aedín Cassidy
Journal:  Am J Clin Nutr       Date:  2016-02-03       Impact factor: 7.045

4.  S-Equol ameliorates insulin secretion failure through Chrebp/Txnip signaling via modulating PKA/PP2A activities.

Authors:  Ka Chen; Hedong Lang; Li Wang; Kai Liu; Yong Zhou; Mantian Mi
Journal:  Nutr Metab (Lond)       Date:  2020-01-14       Impact factor: 4.169

Review 5.  Maximizing the Estrogenic Potential of Soy Isoflavones through the Gut Microbiome: Implication for Cardiometabolic Health in Postmenopausal Women.

Authors:  Lindsay M Leonard; Mun Sun Choi; Tzu-Wen L Cross
Journal:  Nutrients       Date:  2022-01-27       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.